Loading insider details...
Beta
Latest Form 4 (Jun 9, 2026): Grant/Award of 30,000 CHRS shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 9, 2026 | Coherus Oncology, Inc. (CHRS) | Grant/Award | 30,000 | n/a |
| Jun 13, 2025 | Coherus Oncology, Inc. (CHRS) | Grant/Award | 112,000 | n/a |
| Jun 5, 2024 | Coherus BioSciences, Inc. (CHRS) | Grant/Award | 168,000 | n/a |
| May 5, 2023 | Merck & Co., Inc. (MRK) | Exercise/Conversion | 803 | $94.7K |
| May 4, 2023 | Merck & Co., Inc. (MRK) | Grant/Award | 9,682 | n/a |
| May 3, 2023 | Merck & Co., Inc. (MRK) | Exercise/Conversion | 930 | $107.4K |
| Jan 25, 2023 | Merck & Co., Inc. (MRK) | Grant/Award | 2,846 | $312.7K |
| Nov 1, 2022 | Merck & Co., Inc. (MRK) | Exercise/Conversion | 16,997 | n/a |
| May 5, 2022 | Merck & Co., Inc. (MRK) | Exercise/Conversion | 949 | $82.7K |
| May 4, 2022 | Merck & Co., Inc. (MRK) | Exercise/Conversion | 902 | $79.1K |